The Effect of PXR Activation on Blood Pressure Regulation

U

University of Oulu

Status and phase

Completed
Phase 4

Conditions

Blood Pressure Regulation

Treatments

Drug: Placebo
Drug: Rifampicin

Study type

Interventional

Funder types

Other

Identifiers

NCT01690104
Rifa-BP
2011-005522-22 (EudraCT Number)

Details and patient eligibility

About

We are investigating the effects of pregnane X receptor (PXR) activation on the regulation of blood pressure in healthy volunteers. Rifampicin (an antibiotic and also an efficient PXR activator) and placebo will be given for a week to volunteers and blood pressure is measured 24 hours using an ambulatory blood pressure monitor. Blood pressure regulating hormones will be measured in blood. Our hypothesis is that PXR is involved in the regulation of blood pressure.

Enrollment

22 patients

Sex

All

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy volunteers
  • BMI 19-30 kg/m2
  • Age 18-40 years
  • Systolic blood pressure 95 - 140 mmHg

Exclusion criteria

  • Any continuous medication
  • Any significant medical condition as judged by the study physician
  • Diastolic blood pressure over 90 mmHg
  • Sensitivity to rifampicin
  • Pregnancy and lactation
  • Difficult venipuncture
  • Abuse of alcohol or medications, or drug use.
  • Participation in other trial with medications in previous 30 days

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Single Blind

22 participants in 2 patient groups, including a placebo group

Rifampicin
Active Comparator group
Description:
Rifampicin 600 mg daily
Treatment:
Drug: Rifampicin
Placebo
Placebo Comparator group
Description:
Placebo daily
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems